Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared with Vitamin K Antagonists in Patients with Atrial Fibrillation and Type 2 Valvular Heart Disease: A Systematic Review and Meta-Analysis.

Cardiovasc Drugs Ther · 2025 · PMC12717196 · PMID 39153114

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The ROCKET AF trial suggested an increased risk of major bleeding with rivaroxaban compared to warfarin, while the risk of ICH did not reach statistical significance, which may be attributed to the type 2 VHD population’s characteristics: a mean CHA2DS2-VASc score of 3.5, a mean HAS-BLED score of 2.8, and an older age demographic (mean, 75 years), indicating a higher stroke and bleeding risk.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.